Understand the source comparison
Cerebrolysin Alzheimer's Disease Research: Comparison of Neuroprotective Mechanisms
Different therapeutic approaches to Alzheimer's disease target distinct biological mechanisms. And understanding these differences clarifies why Cerebrolysin research explores a path divergent from mainstream drug development. Amyloid-targeting mAbs (aducanuma
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different therapeutic approaches to Alzheimer's disease target distinct biological mechanisms. And understanding these differences clarifies why Cerebrolysin research explores a path divergent from mainstream drug development.
- Amyloid-targeting mAbs (aducanumab, lecanemab)
- Bind amyloid-beta plaques; promote microglial clearance
- Lecanemab: 27% slower decline on CDR-SB at 18 months vs placebo
- Requires early-stage diagnosis; risk of ARIA (brain swelling/microbleeds); minimal functional improvement
- Addresses pathology marker but limited cognitive restoration. Benefit marginal relative to risk profile
- Cholinesterase inhibitors (donepezil, rivastigmine)
- Inhibit acetylcholinesterase; increase synaptic acetylcholine
- 2–4 point ADAS-cog improvement; effects plateau after 6–12 months
- Symptomatic only; no disease modification; GI side effects in 30–40%
- Standard of care for mild-moderate AD but does not slow neurodegeneration. Treats symptom, not cause
- NMDA antagonists (memantine)
- Blocks excessive NMDA receptor activation; reduces excitotoxicity
- Modest benefit in moderate-severe AD; often combined with cholinesterase inhibitors
- Limited efficacy in mild AD; cognitive benefit ~2 points MMSE
- Neuroprotective in theory but clinical benefit modest. Most useful as adjunct therapy
- Cerebrolysin peptide preparation
- Neurotrophic peptide receptor agonism; promotes synaptic repair and neuronal survival
- 3–4 point ADAS-cog improvement; sustained at 24-week follow-up in multiple RCTs
- Requires parenteral administration; optimal dosing and duration still debated
- Targets regenerative pathways neglected by other therapies. Mechanistically distinct and potentially synergistic with standard treatments